WisdomAI’s agentic analytics platform — natively embedded in Tera — delivers natural-language analytics, single-prompt Live Apps, and proactive AI agents across all enterprise data, achieving 95%+ insight accuracy.

SAN FRANCISCO, Sept. 22, 2026 /PRNewswire/ — WisdomAI today announced that its Agentic Analytics platform is now embedded natively in Teradata‘s (NYSE: TDC) new agentic coworker for enterprise data work, Tera, available within Teradata’s Autonomous Knowledge Platform in the fall of 2026. The integration brings WisdomAI’s deterministic agentic analytics platform to Teradata’s enterprise customers, letting business users talk to their data in natural language, build live apps from a single prompt, and deploy proactive AI agents that monitor KPIs, surface root causes, and drive the next action across structured, semi-structured, and unstructured data alike.

WisdomAI was built for the architecture enterprises actually run: data that lives in many places, under many controls, and rarely moves. Its architecture reasons across structured warehouses, semi-structured logs, and unstructured documents in a single query without copying, re-pipelining, or exposing data to external models. Inside Tera, WisdomAI executes every query directly on Teradata’s governed data foundation, with security, lineage, and access controls fully intact, making over 95% accurate agentic BI viable on the regulated, high-performance workloads that have historically been off-limits to AI-driven analytics.

The integration also brings WisdomAI together with Tera Context Engine, which gives agents governed business context including industry data models, canonical metrics, business logic, lineage, and policies. Pre-curated definitions and semantic context allow more work to move from probabilistic reasoning to deterministic execution, while Teradata’s governance, data modeling, and mapping agents keep that context current as data, policies, and definitions change. The result is more accurate, reliable agentic analytics without requiring enterprises to move their data or replace existing investments.

“WisdomAI was built for one job: to deliver trusted, accurate answers on enterprise data — the kind of data the business actually depends on, often regulated, often on-premises, almost always too important for a probabilistic guess,” said Soham Mazumdar, co-founder and CEO of WisdomAI. “Teradata’s customers run exactly that data, and Tera is the right place to deliver agentic analytics to them. This partnership is a force multiplier for both sides of the data conversation. Business users finally get to interact with their data directly, and data teams get an AI partner that respects the governance, performance, and rigor they’ve built.”

“The Teradata platform is built to bring enterprise-grade AI to the regulated and mission-critical data our customers can’t afford to compromise on,” said Sumeet Arora, Chief Product Officer at Teradata. “Embedding WisdomAI’s agentic analytics platform directly into Tera means business users can do more with that data without changing where it lives or how it’s governed. That’s exactly the kind of partnership we look for. One that respects the architecture our customers have built and amplifies what they can already do with it.”

The result is a new operating model for enterprise analytics: business users get answers in the time it takes to type a question, data teams reclaim hours spent on routine requests, and decisions no longer wait for the next meeting. As enterprises move from AI pilots to AI production, the platforms that win will be those that deliver accuracy, governance, and federated reach as a single system; exactly what WisdomAI was built to do and exactly what Teradata AI Studio was built to support.

The integration will be generally available with the Teradata Autonomous Knowledge Platform on Teradata Cloud in the fourth quarter of 2026, with availability on Teradata Factory to follow.

To learn more about the WisdomAI and Teradata partnership, visit www.wisdom.ai/partners/teradata.

About WisdomAI
WisdomAI is the leader in a new generation of AI analytics and business intelligence, with the first Agentic Analytics Platform that delivers trusted, accurate, and proactive insights for the enterprise. Founded in 2023, WisdomAI empowers organizations to reason across their structured and unstructured data in natural language with Conversational BI, build Live Apps instantly with a single prompt, and deploy autonomous Proactive Agents that act on insights.

Teradata Forward-Looking Statements
This press release contains “forward-looking statements” about the expectations, beliefs, plans, and intentions relating to Tera, including Tera Context Engine, Tera Harness, and Agent Skills. Such statements include statements regarding future product availability, capabilities, and offerings, and expected benefits to Teradata customers. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, Teradata’s results could differ materially from the results expressed or implied by the forward-looking statements made. Teradata undertakes no obligation, and does not intend to update the forward-looking statements. Factors that may cause actual results to differ materially from those in any forward-looking statements include: (i) delays and unexpected difficulties and expenses in executing the planned product capabilities and offerings, (ii) changes in the regulatory landscape related to AI and (iii) uncertainty as to whether customer adoption will justify the investments in the product capabilities and offerings. Further information on factors that could affect Teradata’s financial and other results is included in the filings Teradata makes with the Securities and Exchange Commission from time to time.

View original content:https://www.prnewswire.com/news-releases/wisdomai-and-teradata-partner-to-deliver-agentic-intelligence-for-mission-critical-enterprise-data-302886377.html

SOURCE WisdomAI

New Season Premieres September 14 Across Out Magazine’s YouTube Network, Podcast Platforms, and OutLoudAndLaughing.com

NEW YORK, Sept. 22, 2026 /PRNewswire/ — Hit comedy interview series Out Loud and Laughing today announced its highly anticipated fourth season, partnering with leading LGBTQ+ media powerhouse equalpride (parent company of Out and The Advocate) for a major cross-platform distribution expansion. Premiering September 14, 2026, Season 4 will roll out across all major podcast platforms, the official website OutLoudAndLaughing.com, social channels, and Out Magazine’s newly revamped YouTube network.

Hosted by creators Bryan Ruiz and Jon Ruiz, Season 4 expands the show’s signature mix of bold comedy, unfiltered culture conversations, and candid interviews. The upcoming season features a dynamic slate of filmed talent alongside upcoming guest appearances, including:

Daniel Reynolds, Editor-in-Chief of Out MagazineRicky Cornish, Entertainment Editor at equalprideClaybourne Elder, Actor/SingerJake Graf, Actor/ScreenwriterJudy Gold, Comedian/ActorPaul Wagner, Actor/Adult StarChris Salvatore, Actor/SingerMaria Sjödin, ActivistDan Jinks, Film Producer (American Beauty, Milk, Big Fish)

NOW BOOKING: SEASON 4 TALENT CALLOUT 
As Out Loud and Laughing expands its footprint this season, the show is actively booking guests across the entire LGBTQIA+ spectrum. The platform is seeking compelling voices from entertainment, medicine, science, business, advocacy, and everyday culture makers doing groundbreaking work. Representatives and publicists looking to pitch talent for Season 4 appearances should contact [Insert Contact Email].

“We are thrilled to welcome Out Loud and Laughing into the Out family as we expand our digital video footprint,” said Mark Berryhill, CEO of equalpride. “As we relaunch Out Magazine’s YouTube platform, bringing Out Loud and Laughing on board perfectly aligns with our mission to elevate LGBTQ+ voices, foster joy, and deliver world-class entertainment alongside our trusted journalism and advocacy.”

With Out’s YouTube relaunch, audiences gain centralized access to premium video content from equalpride’s iconic portfolio—including Out, The Advocate, Out100, and Plus.

Season 4 of Out Loud and Laughing premieres September 14. Viewers can stream directly at youtube.com/outmagazine or listen wherever podcasts are available.

About equalpride
equalpride is the leading LGBTQ+-owned media company in the United States, delivering content across print, digital, streaming, and live events. Its portfolio includes iconic brands such as Out, The Advocate, Out100, Plus, and PRIDE.com, dedicated to inspiring, entertaining, and empowering the LGBTQ+ community worldwide.

About Out Loud and Laughing
Created and hosted by New York-based duo Bryan Ruiz and Jon Ruiz, Out Loud and Laughing is a celebrated comedy platform and interview show highlighting the funniest, boldest, and most vibrant voices in the LGBTQ+ community and beyond.

Media Contact & Booking Pitch Submissions: BryanAndJon@outloudandlaughing.com

Media Kit

PRESS CONTACT: Bryan Ruiz and Jon Ruiz | bryanandjon@outloudandlaughing.com | +1 917-981-7742

View original content to download multimedia:https://www.prnewswire.com/news-releases/hit-comedy-series-out-loud-and-laughing-announces-season-4-lineup-featuring-chris-salvatore-paul-wagner-equalpride-leadership–more-302885187.html

SOURCE Out Loud and Laughing

Collaboration will integrate Sanguina‘s AI-enabled patented fingernail analysis technology into My Pediatric Doctor and My Adult Doctor, with future applications through My VA Doctor and My Oncology Doctor and across maternal health, veterans’ health, oncology, hospital systems, clinical trials, and global healthcare initiatives.

CHARLOTTE, N.C. and ATLANTA, Sept. 22, 2026 /PRNewswire/ — QC Healthcare, a national healthcare innovation company focused on transforming patient access through technology, artificial intelligence, and connected care solutions, today announced a strategic collaboration with Sanguina, an AI-powered digital health company specializing in non-invasive fingernail analysis to derive blood health insights.

Through this collaboration, QC Healthcare will integrate Sanguina‘s innovative AI-driven screening capabilities for anemia, circulation, and other blood-health risk profiles across its growing healthcare ecosystem. The initial deployment will focus on My Pediatric Doctor, a nationwide 24/7 pediatric urgent care and primary care telehealth platform, and My Adult Doctor, a national 24/7 adult urgent care and primary care platform, with future applications planned for My VA Doctor and My Oncology Doctor.

The collaboration represents a significant advancement in the shared mission of QC Healthcare and Sanguina to deliver proactive, accessible, technology-enabled healthcare by bringing advanced screening tools directly into virtual care pathways. By leveraging artificial intelligence, digital biomarkers, and accessible patient-centered technology, QC Healthcare and Sanguina aim to improve early identification of issues in blood health, enhance remote clinical decision-making, and support more personalized healthcare delivery.

Addressing Global Healthcare Challenges Through Accessible Detection and Tracking

Anemia remains one of the most common blood-related conditions worldwide, affecting an estimated 1.9 billion people. Children, adults, pregnant and postpartum women, older adults, individuals with chronic diseases, cancer patients, and frequent blood donors are among the populations that may face elevated anemia risk and associated complications.

Most people learn their hemoglobin is low only when a lab draw happens to catch it. Between appointments, both patients and their care teams have no visibility at all. Sanguina‘s technology was built to close that gap, enabling frequent or on demand and personalized anemia screenings.

Additionally, Sanguina‘s circulation technology turns a fingernail video into a second measure of blood health. The Circulation Score quantifies the time and speed at which blood returns to the fingertips after they are briefly pressed and released, digitizing a bedside assessment clinicians have long used when evaluating peripheral perfusion. In the home setting, objective circulation trends may provide useful context for telehealth evaluations and may help clinicians determine whether follow-up assessment is appropriate for patients with symptoms or conditions associated with impaired circulation, dehydration, vascular disease, diabetes, cardiovascular concerns, recovery after illness or surgery, and other acute or chronic health needs. The score is intended to support screening, monitoring, and clinical decision-making; it is not, by itself, a diagnosis or a replacement for laboratory testing, physical examination, or emergency evaluation when indicated.

Integration into QC Healthcare‘s platforms puts it into use at national scale. By incorporating AI-enabled screening capabilities into digital healthcare workflows, QC Healthcare and Sanguina anticipate that patients can be identified earlier, evaluated more efficiently, and connected with appropriate clinical pathways before conditions become more serious.

“This collaboration represents the future direction of healthcare – moving from reactive treatment toward earlier identification, informed follow-up, and prevention,” said Eric Doherty, CEO of QC Healthcare. “By combining QC Healthcare‘s nationwide virtual care ecosystem with Sanguina‘s innovative AI technology, we can help bring meaningful blood-health information into the home and connect it to licensed clinical care. That opportunity extends across the families served by My Pediatric Doctor and My Adult Doctor today, as well as pregnant and postpartum women, veterans, and people navigating cancer who may benefit from the future My VA Doctor and My Oncology Doctor platforms.”

“Telehealth medicine enables accessible care,” said Erika Tyburski, CEO and Co-Founder of Sanguina. “Our fingernail analysis technologies push the accessible model further by equipping telehealth with on-demand tools that can be used at home to help fill missing data points between clinical interactions. Working with QC Healthcare creates an opportunity to connect anemia and circulation insights with care pathways serving children, adults, pregnant and postpartum women, veterans, and oncology patients at national scale.”

The initial focus of the collaboration will include integrating anemia and circulation screening into My Pediatric Doctor and My Adult Doctor, followed by evaluation of future applications across QC Healthcare‘s expanding platform portfolio.

Pediatric and Adult Virtual Care

Across My Pediatric Doctor, a nationwide 24/7 pediatric urgent care and primary care telehealth platform, anemia is a routine concern in childhood development, nutrition, and chronic disease management – and one that ordinarily requires a lab visit to investigate. My Adult Doctor, QC Healthcare‘s national 24/7 adult platform, serves patients managing fatigue and unexplained symptoms, adults with chronic conditions requiring ongoing monitoring, women during pregnancy and after childbirth, and patients participating in preventive health evaluations. In both settings, a between-visit blood-health history can provide clinicians with added context when deciding whether laboratory testing, an in-person examination, referral, or other follow-up is warranted.

Maternal Health, Oncology, and Veterans’ Care

Pregnancy and the postpartum period are major areas of potential impact. Iron needs rise during pregnancy, and blood loss during delivery can contribute to postpartum anemia. When clinically appropriate, convenient at-home screening and trend information could help women and their care teams recognize changes sooner, support follow-up after delivery, and connect patients with confirmatory testing and treatment. QC Healthcare‘s relationship with families through My Adult Doctor and My Pediatric Doctor creates a natural bridge between maternal care and pediatric care during a period when mothers may otherwise place their own health needs behind those of a newborn. Cancer patients may experience anemia related to disease, treatment, blood loss, or nutrition, and QC Healthcare‘s planned My Oncology Doctor platform is intended to support monitoring and care coordination between oncology visits. My VA Doctor, also in development, will extend appropriate blood-health and circulation applications to veterans, including those managing chronic disease, mobility limitations, recovery needs, or barriers to in-person care.

Building a Digital Blood Health Network

The collaboration draws on capabilities both companies are assembling into a single connected care network — artificial intelligence, telehealth, digital diagnostics, remote monitoring, data analytics, clinical research, and preventive care operating as one pathway rather than seven separate services. That integration is also what makes the model portable. The infrastructure gap that keeps a rural patient from a routine blood panel is the same gap facing health organizations across much of the world, and both companies intend to pursue international deployments, working with healthcare organizations abroad to adapt the model for populations where laboratory access is thinnest, and the need is greatest.

Health Systems, Payers, and Employers

Beyond direct-to-patient virtual care, the two companies will pursue potential deployments with hospitals, health systems, employers, payers, maternal-health programs, veterans’ organizations, oncology programs, and research partners. Potential applications include remote monitoring, population health and chronic disease management, prenatal and postpartum follow-up, discharge follow-up, preventive health campaigns, and clinically guided pathways for additional evaluation.

Clinical Research and Evidence Generation

The collaboration will also support clinical validation studies, real-world evidence generation, and clinical trial recruitment and coordination, drawing on Sanguina‘s published clinical data and QC Healthcare‘s nationwide patient reach. Any expansion into new clinical uses will follow appropriate clinical validation and regulatory review.

Working with QC Healthcare and Sanguina

Health systems, payers, employers, maternal-health organizations, veterans’ organizations, oncology programs, blood collection organizations, and research partners interested in exploring deployments can contact QC Healthcare through its platform websites or Sanguina at partnerships@sanguina.ai.

About QC Healthcare

QC Healthcare is a healthcare holding and innovation company focused on building and scaling connected healthcare businesses through artificial intelligence, digital health technologies, nationwide virtual care, strategic partnerships, clinical research, and data-driven solutions.

Through its growing ecosystem – including My Pediatric Doctor and My Adult Doctor, with My VA Doctor and My Oncology Doctor in development – QC Healthcare is creating a connected model of care designed to improve access, strengthen continuity, support better-informed clinical decisions, and accelerate responsible healthcare innovation. Learn more and follow QC Healthcare on LinkedIn.

About Sanguina

Sanguina is an AI-powered digital health company focused on improving awareness, screening, tracking, and management of blood health through accessible and innovative technology solutions. The company is led by CEO and Co-Founder Erika Tyburski.

The company’s technology platform represents a new approach to leveraging artificial intelligence and digital health tools to enable and support non-invasive health measurements on demand, in remote, point-of-care and home settings. Learn more at Sanguina.com and follow Sanguina on LinkedIn.

About My Pediatric Doctor

My Pediatric Doctor provides nationwide, 24/7 pediatric urgent and primary care telehealth, giving families convenient access to experienced U.S.-based clinicians across all 50 states, Puerto Rico, and Guam. The platform accepts insurance and also supports direct-pay access. Learn more at MyPediatricDoctor.com or follow My Pediatric Doctor on LinkedIn.

About My Adult Doctor

My Adult Doctor provides nationwide, 24/7 adult urgent and primary care telehealth across all 50 states, Puerto Rico, and Guam. Its connected care model is designed to support acute needs, preventive care, chronic disease management, medication management, laboratory ordering, referrals, care coordination, and wellness services. Learn more at MyAdultDoctor.com or follow My Adult Doctor on LinkedIn.

Media Contact

QC Healthcare and My Adult Doctor: contact@MyAdultDoctor.com | My Pediatric Doctor: contact@MyPediatricDoctor.com | Sanguina: partnerships@sanguina.ai

View original content to download multimedia:https://www.prnewswire.com/news-releases/qc-healthcare-announces-strategic-collaboration-with-sanguina-to-deploy-ai-powered-blood-health-technologies-across-nationwide-healthcare-platforms-302886131.html

SOURCE QC Healthcare